Our study indicates a significant correlation between high ISG15 levels and not only LVI but also with other features of aggressive tumour behaviour including high tumour grade, large tumour size, hormone receptor negativity and overexpression of HER2, the immune cell markers, MMPs and the BC stem cell markers in addition to poor patient outcome. This evidence concerns the gene ERBB2 and breast cancer.